[Allogeneic hematopoietic stem cell transplantation for multiple myeloma]

Area of Science:

• Hematology
• Oncology
• Immunotherapy

Context:

• Multiple myeloma (MM) treatment has advanced with autologous hematopoietic stem cell transplantation (HSCT) and novel agents, significantly extending patient survival.
• Despite progress, multiple myeloma remains an incurable malignancy, necessitating exploration of more effective therapeutic strategies.
• Allogeneic HSCT presents a potentially curative approach for MM, leveraging the graft-versus-myeloma (GVM) effect.

Purpose:

• To review and analyze the evolving landscape of stem cell transplantation for multiple myeloma.
• To evaluate the efficacy and safety of different HSCT approaches, including reduced-intensity conditioning and tandem transplants.
• To assess the integration of novel therapeutic agents with allogeneic HSCT to enhance anti-myeloma activity and mitigate treatment-related mortality.

Summary:

• Autologous HSCT combined with novel agents has improved MM outcomes but not achieved cures.
• Allogeneic HSCT offers curative potential through the GVM effect but is limited by high treatment-related mortality.
• Investigational strategies include reduced-intensity conditioning, sequential autologous-allogeneic HSCT, and novel agent incorporation before/after allogeneic HSCT.

Impact:

• This research highlights the ongoing challenges in MM treatment and the potential of allogeneic HSCT as a curative option.
• It underscores the importance of optimizing conditioning regimens and incorporating novel agents to improve the safety and efficacy of allogeneic HSCT.
• Findings may guide future clinical trial designs and treatment protocols aimed at achieving long-term remission or cure for multiple myeloma patients.